Table 1

Change in efficacy variables, means (95% CI)

VariableChange from baseline to week 52
SSZMTXCOMBI
DAS−1.8 (−2.3,−1.3)−2.0 (−2.4,−1.7)−2.3 (−2.7,−1.9)
Number of swollen joints−9.2 (−12.2,−6.3)−12.4 (−15.4,−9.5)−14.3 (−17.3,−11.4)
Ritchie articular index−9.2 (−11.7,−6.8)−9.5 (−11.6,−7.5)−10.6 (−12.5,−8.7)
Number of painful joints−12.5 (−15.9,−9.1)−15.2 (−18.2,−12.2)−16.9 (−20.4,−13.5)
VAS general health (mm)−15.4 (−25.8,−5.0)−21.3 (−30.2,−12.3)−20.6 (−27.6,−13.7)
ESR (mm/h)−17 (−26,−8)−21 (−28,−15)−28 (−37,−19)
  • MTX: methotrexate, COMBI: combination of methotrexate and sulphasalazine, SSZ: sulphasalazine, DAS: Disease Activity Score, VAS: Visual Analogue Scale (0–100 mm).